by Ben Winward
Posted in Pharmaceuticals
The emergence of covid-19 and resulting lockdowns sparked fears for the global supply of generics and biosimilars. With the industry being heavily reliant on China for APIs and India for the manufacture of generic drugs, the disruption caused by covid-19 had the potential to wreak havoc across the whole supply chain.